Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Onyvax-105, Onyvax.

Rosalyn D Blumenthal1

  • 1Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA. rblumenthal@gscancer.org

Current Opinion in Molecular Therapeutics
|February 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types.

PPAR research·2008
Same author

Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.

Radiation research·2007
Same author

Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Molecular biotechnology·2007
Same author

Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.

Anti-cancer drugs·2007
Same author

Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.

BMC cancer·2007
Same author

Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).

Cancer research·2005

Onyvax-105 is an investigational anti-idiotype monoclonal antibody therapy for colorectal cancer. Phase II clinical trials commenced in May 2000 to evaluate its therapeutic potential.

Area of Science:

  • Oncology
  • Immunotherapy
  • Monoclonal Antibody Development

Background:

  • Colorectal cancer remains a significant global health challenge.
  • Novel therapeutic strategies are continuously being explored to improve patient outcomes.
  • Anti-idiotype antibodies represent a promising class of targeted therapies.

Purpose of the Study:

  • To evaluate the safety and efficacy of Onyvax-105 (105AD7) in patients with colorectal cancer.
  • To assess the potential of Onyvax-105 as a targeted immunotherapy.
  • To advance the development of novel colorectal cancer treatments.

Main Methods:

  • Development of Onyvax-105, an anti-idiotype monoclonal antibody, under license from the Cancer Research Campaign.
  • Initiation of Phase II clinical trials in May 2000.

Related Experiment Videos

  • Evaluation of therapeutic response and patient tolerance.

    • Main Results:

    • Phase II clinical trials were initiated in May 2000.
    • Data on efficacy and safety are pending further trial progression.

    Conclusions:

    • Onyvax-105 is under investigation as a potential treatment for colorectal cancer.
    • The initiation of Phase II trials marks a critical step in its clinical development.
    • Further research is necessary to establish its role in colorectal cancer therapy.